IGEA Pharma N.V.

IGEA to get SIX approval to delay the 2021 annual report disclosure - Seite 2

- the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position;

- the reasons for the application of the Issuer requesting an extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG;

- the unaudited key figures such as net revenues, EBITDA, EBIT, profit/loss, balance sheet total, equity etc. for the annual results 2021."

The unaudited key figures for 2021 are anticipated as follow:

- The group generated marginal revenue of TUSD 116 (2020: TUSD 166);

- Cost of sales was TUSD 66 (2020: TUSD 359);

- Gross Profit was TUSD 51 (2020: TUSD -193);

- Operating expenses were TUSD 1'010 (2020: TUSD 1'447). The significant decrease is mainly due to the reduction of the sales and marketing expenses and to the ongoing optimization on general and administration. Other income, net of other expenses, related to certain non-core operations for TUSD -53 (2020: -124) contributed furthermore to decrease operating expenses;

- EBITDA as adjusted (before impairment charges) and EBIT is TUSD -1'012 (2020: TUSD - 1'764) and TUSD -863 (2020: TUSD -1,989) respectively;

- finance result TUSD 149 (2020: TUSD -225);

- the net loss is TUSD 863 (2020: TUSD 1,991);

- Total assets are TUSD 14'617 (2020: TUSD 10'590), with a Group equity of TUSD 11'247 (2020: TUSD 8'098)

***

About IGEA

IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline. The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.